PLRX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107882 min ago

@ $16.43

Išleistas: 14 vas. 2024 @ 22:44

Grąža: -25.84%

Ankstesnis signalas: vas. 14 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: 5.47 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 21:44):

Stats
Šios dienos apimtis	158 101
Vidutinė apimtis	371 556
Rinkos kapitalizacija	734.68M
EPS	$-0.690 ( 2024-03-28 )
Kita pelno data	( $-0.770 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.43
ATR14	$0.0230 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Lefebvre Eric	Buy	42 900	Common Stock
2024-01-23	Lefebvre Eric	Buy	85 800	Stock Option (Right to Buy)
2024-01-23	Hull Hans	Buy	31 500	Common Stock
2024-01-23	Hull Hans	Buy	63 000	Stock Option (Right to Buy)
2024-01-23	Ouimette Mike	Buy	31 500	Common Stock

INSIDER POWER
67.14
Last 98 transactions
Buy: 2 502 892 \| Sell: 552 083

Tūris Koreliacija

Ilgas: -0.06 (neutral)

Trumpas: -0.36 (neutral)

Signal:(28.718) Neutral

Pliant Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
PAIC	0.955
CSII	0.935
ADMS	0.932
RESN	0.927
HSKA	0.921
ZGNX	0.918
OLMA	0.915
NATI	0.914
IPW	0.912
SVAC	0.911

10 Labiausiai neigiamai susiję koreliacijos
NETE	-0.945
BOCH	-0.932
MMAC	-0.914
RAVN	-0.912
SHSP	-0.879
SBBP	-0.876
CFV	-0.873
AMRB	-0.869
ORMP	-0.869
AZTA	-0.861

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Pliant Therapeutics Inc Koreliacija - Valiuta/Žaliavos

0.43
( neutral )

0.54
( weak )

0.00
( neutral )

0.67
( moderate )

0.72
( moderate )

-0.83
( strong negative )

Pliant Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$1.58M
Bruto pelnas:	$-261 000 (-16.52 %)
EPS:	$-2.75

FY	2023
Pajamos:	$1.58M
Bruto pelnas:	$-261 000 (-16.52 %)
EPS:	$-2.75

FY	2022
Pajamos:	$9.69M
Bruto pelnas:	$6.00M (61.99 %)
EPS:	$-2.89

FY	2021
Pajamos:	$7.57M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.71

Financial Reports:

No articles found.

Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.